About us

Forging the path for Iron Therapies: Market analysis and competitive intelligence on IV Iron products and substitutes in Europe.

The project defines how the client can expand IV iron adoption and win share against competing formulations and oral alternatives. It focuses commercial investment on therapy areas where clinical need, treatment access, and product differentiation support credible growth.

Outcome

  • Prioritized opportunities across therapy areas and care settings, distinguishing clinical need from realistic commercial potential.
  • Clear competitive positioning against other IV iron formulations and oral alternatives, based on clinical evidence, treatment convenience, and provider economics.
  • Identification of market access barriers related to reimbursement, formularies, procurement, and infusion capacity.
  • Focused commercial roadmap linking priority specialties and accounts with the evidence and engagement needed to strengthen adoption.

KEY INTELLIGENCE OBJECTIVES

  • Estimate IV iron market volume and value by formulation, therapy area and care setting, distinguishing eligible patient populations from diagnosed and treated demand.
  • Map diagnosis, referral and treatment pathways across priority specialties, identifying gaps in iron deficiency detection, treatment initiation, and access to infusion services.
  • Assess the role of oral iron and other anaemia-management approaches, distinguishing direct alternatives from complementary treatments and identifying when IV iron enters the treatment pathway.
  • Benchmark competing IV iron products by market share, clinical evidence, safety profile, dosing flexibility, administration requirements, and commercial positioning.
  • Identify what drives prescriber preference and brand selection, including experience with existing products, perceptions of clinical benefit, safety concerns, and willingness to change prescribing practices.
  • Examine reimbursement, formulary inclusion and hospital procurement, including tender criteria, negotiated pricing and the influence of clinicians, pharmacists and purchasing teams.
  • Evaluate treatment economics beyond drug acquisition price, including infusion visits, staff time, monitoring requirements, and capacity constraints that influence provider decisions.
  • Analyze competitor strategies for specialty expansion, clinical education, and account development, assessing how emerging evidence, guideline changes, and new products may reshape demand.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.